{
  "main_header": {
    "sid": 178818,
    "name": "Ajanta Pharma",
    "stock_name": "Ajanta Pharma",
    "full_name": "Ajanta Pharma Ltd.",
    "name_url": "stocks-analysis/ajanta-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,797.80",
    "chg": -23.55,
    "chgp": "-0.83%",
    "dir": -1,
    "prev_price": "2,821.35",
    "mcapval": "34,659.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": 532331,
    "symbol": "AJANTPHARM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE031B01049",
    "curr_date": "Apr 02",
    "curr_time": "",
    "bse_nse_vol": "55.87 k",
    "exc_status": "Active",
    "traded_date": "Apr 02, 2026",
    "traded_date_str": "2026 04 02",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/ajanta-pharma-178818-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [],
    "total": 0,
    "sid": "178818",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/ajanta-pharma-178818"
  },
  "announcements": [
    {
      "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
      "datetime": "01-Apr-2026",
      "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Ajanta Pharma Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230MH1979PLC022059</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>A1+</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>CARE RATINGS LIMITED</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>NSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Gaurang Shah <br/> Designation: Sr VP Legal and Company Secretary <br/> EmailId: gaurang.shah@ajantapharma.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Arvind Agrawal <br/> Designation: Chief Financial Officer <br/> EmailId: gaurang.shah@ajantapharma.com</div> </div> <div> <br/> Date: 01/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
      "datetime": "01-Apr-2026",
      "details": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on March 31 2026 for Ravi Agrawal trustee Ravi Agrawal Trust",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
      "datetime": "27-Mar-2026",
      "details": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on March 27 2026 for Aayush Agrawal & Others",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Ajanta Pharma Ltd. has declared <strong>1400%</strong> dividend, ex-date: 10 Nov 25",
          "dt": "2025-11-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Ajanta Pharma Ltd. has announced <strong>2:5</strong> stock split, ex-date: 20 Mar 15",
          "dt": "2015-03-20",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Ajanta Pharma Ltd. has announced <strong>1:2</strong> bonus issue, ex-date: 22 Jun 22",
          "dt": "2022-06-22",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

No Recent News for the Company

View All News